September 23, 2019
  • September 23, 2019
Breaking News

Health

Immunomedics, Inc. (NASDAQ:IMMU) executive board chair indirectly purchase million more shares

by on July 3, 2019 0

Immunomedics, Inc. (NASDAQ:IMMU) saw its executive board chair, Behzad Aghazadeh, step up again and indirectly purchase a million more shares of this biopharmaceutical company. At prices ranging from $13.21 to $13.84 per share, that cost him almost $13.55 million. The insider ownership percentage is the key indicator, can be used by investors, to measure...

Read More

Don’t Miss: Xenetic Biosciences, Inc. (NASDAQ:XBIO)

by on July 3, 2019 0

Xenetic Biosciences, Inc. (NASDAQ:XBIO) filed prospectus for offering of 1.6 million shares of common stock & warrants. The insider ownership percentage is the key indicator, can be used by investors, to measure the outlook of senior management has on their company. Insider ownership for the XBIO is 58.20%. Institutional ownership refers to the ownership...

Read More

Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced trial results that could bode well for migraine patients

by on July 3, 2019 0

Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced trial results Tuesday that could bode well for migraine patients. At the Fifth Congress of the European Academy of Neurology held in Oslo, Norway, Teva presented additional positive results from a Phase 3b exploratory study dubbed FOCUS that evaluated its migraine drug fremanezumab in adults who previously experienced...

Read More

Pfizer Inc. (NYSE:PFE) announced top-line results from a Phase 4 study

by on July 2, 2019 0

Pfizer Inc. (NYSE:PFE) announced top-line results from a Phase 4 study (CrisADe CARE 1) which showed that crisaborole ointment, 2%, was well-tolerated in children aged 3 months to less than 24 months with mild to moderate atopic dermatitis (AD), also known as eczema. The data from the trial are supportive of the primary study...

Read More

Neuralstem, Inc. (NASDAQ:CUR) announced publication of manuscript in Stem Cells Translational Medicine

by on July 2, 2019 0

Neuralstem, Inc. (NASDAQ:CUR) announced the publication of a manuscript in Stem Cells Translational Medicine describing the results of an open label Phase 1 clinical trial evaluating the feasibility and safety of transplantation of its lead stem cell asset, NSI-566, for the treatment of motor deficits due to ischemic stroke. The insider ownership percentage is...

Read More